Clinical Trial Update: Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the effect of steady-state BIA 6-512 on levodopa pharmacokinetics in Parkinson disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 6-512
• levodopa (levodopa)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson Disease | Phase 1 | Status: COMPLETED